



Global Pharmaceutical Leader Aurobindo Presents AuroSource, its new division for Custom Research and Manufacturing (CRAMS)

4th March 2010

Global pharmaceutical leader Aurobindo Pharma Limited introduces AuroSource, a service oriented and customer-centric division within the company that will provide custom R&D and manufacturing (CRAMS) services for large, mid-sized and emerging biotech and pharmaceutical entities globally.

AuroSource will partner with these companies and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. This division of the Hyderabad based company is uniquely poised to deliver:

- Fully consolidated or customized manufacturing solutions for Active Pharmaceutical Ingredients (APIs), Intermediates, Pre-Formulations and Formulations across each stage of the pharmaceutical life cycle;
- Regulatory, Research and Development Expertise from the pre-clinical stage through the post patent expiry phase in drug development;
- Premium solutions for product life cycle management including life cycle extensions and line extensions.

AuroSource's parent company, Aurobindo, is one of India's largest pharmaceutical companies with more than U.S. \$800 million in annual sales. The company was founded in 1989 and today has 15 manufacturing facilities for both API and finished dosage - including 10 approved by the U.S. Food & Drug Administration. The company also has significant R&D capabilities which include 750 talented scientists spread across five facilities specializing in process chemistry development, dosage form development and pre-formulations. AuroSource is setting up a modern R&D facility at Pashamylaram to house another 140-150 scientists. Expansion plans are being drafted to also start offering services in fields such as medicinal chemistry and other discovery services.

"AuroSource is uniquely positioned to smoothly transition our competence in drug development to customers within this market segment. We stand to become an invaluable partner in enabling them to streamline and simplify their development and manufacturing processes so they can focus primarily on creating life-saving, low-cost products and contribute to making global healthcare more affordable," said Mr. Ramprasad Reddy, Chairman of Aurobindo Pharma Ltd.

Dr. M. Sivakumaran, Director on the Board of Aurobindo Pharma added: "By combining our research and development expertise with significant capability and facilities, our customers can securely outsource drug development projects while significantly reducing their need to absorb fixed costs around capital investments. AuroSource not only possesses the tools, expertise, assets and financial backing to support outsourcing efforts, but we also have a renewed commitment to optimize the internal selling processes in a seamless manner for our customers which include virtual and small biotech companies, mid-sized partially integrated companies and large vertically integrated companies."

AuroSource officials recognize that this is a critical time to enter this market. Impending reforms in the U.S. healthcare market have exposed a need for contract manufacturing services. Large pharmaceutical manufacturers are reducing their capabilities and consolidating their outsourcing needs for pharmaceutical intermediates and formulated APIs (Active Pharmaceutical Ingredients). The growth of consolidated trust-worthy suppliers creates an untapped market for contract manufacturing services as AuroSource will provide. The AuroSource team organized from the parent company has



commercialized more than 200 APIs and 120 Finished Drug Products which sets the stage for a successful contract service provider. The team will be headed by Dr. R. Ananth (President, AuroSource), who has several years of senior management experience in the CRAMS field. Speaking about the new venture he said, "We offer unmatched manufacturing competence and superior research capabilities, while keeping the whole outsourcing experience in the hands of our customers and enhancing the transparency of the whole process. We are committed to giving each of our customers an unparalleled experience by keeping the process simple for them,"

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/ product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com